title: Calcitonin-specific transcription and splicing targets gene-directed enzyme prodrug therapy to medullary thyroid carcinoma cells.
abstract: Recurrent and metastatic medullary thyroid carcinoma (MTC) remains difficult to treat due to its limited responsiveness to chemotherapy, radiotherapy, and imaging. To investigate an alternative therapeutic approach, we examined the feasibility of targeting gene-directed enzyme/prodrug therapy delivered by adenoviral vectors to MTC. We previously described a modified human calcitonin (CT)/CT gene-related peptide promoter that produced increased expression while maintaining specificity for MTC cells. In this study, we introduced an additional level of specificity by using cell-specific splicing and examined whether the selectivity of the gene-directed enzyme/prodrug therapy for MTC was enhanced when both the promoter and splicing features were combined in a single transcription unit. Two replication-defective adenoviruses were constructed that expressed the Escherichia coli purine nucleoside phosphorylase (PNP) gene under the transcriptional control of a modified T2 promoter (Ad.T2-PNP) or the T2 promoter in combination with a CT minigene cassette in which the PNP gene was imbedded within the CT gene exon 4 (Ad.T2-CT/PNP). The specificity of PNP expression by Ad.T2-PNP, Ad.T2-CT/PNP, and control viruses in the MTC cell line, TT, and in a panel of non-MTC cell lines was evaluated. The highest level of PNP gene expression and the most effective cell killing in the presence of prodrug occurred in TT cells infected with Ad.T2-PNP, followed by Ad.T2-CT/PNP. Infection of most non-MTC cell lines, even with high multiplicities of Ad.T2-PNP, produced only low-level PNP expression that resulted in minimal cell killing in the presence of prodrug. High-level expression of PNP and effective cell killing was observed with both adenoviral gene constructs. The highest level of cell specificity was achieved with the combined use of promoter and splicing regulation in the Ad.T2-CT/PNP virus.
authors.affiliation: Department of Cancer Genetics, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, New South Wales, Australia 2065.
authors.forename: Marinella
authors.initials: M
authors.lastname: Messina
authors.forename: Denise M T
authors.initials: DM
authors.lastname: Yu
authors.forename: Gerald W
authors.initials: GW
authors.lastname: Both
authors.forename: Peter L
authors.initials: PL
authors.lastname: Molloy
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Robinson
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D002116:Calcitonin / Q000235:genetics*; D018276:Carcinoma, Medullary / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D011355:Prodrugs / Q000627:therapeutic use*; D011401:Promoter Regions, Genetic; D011683:Purine-Nucleoside Phosphorylase / Q000235:genetics*; D012326:RNA Splicing; D013964:Thyroid Neoplasms / Q000628:therapy*; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured; D014779:Virus Replication
chemical_list: D011355:Prodrugs; D002116:Calcitonin; D011683:Purine-Nucleoside Phosphorylase